Harvest Fund Management Co. Ltd Trims Holdings in Natera, Inc. (NASDAQ:NTRA)

Harvest Fund Management Co. Ltd decreased its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 33.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,205 shares of the medical research company's stock after selling 2,569 shares during the period. Harvest Fund Management Co. Ltd's holdings in Natera were worth $780,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cerity Partners LLC lifted its position in shares of Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock valued at $10,936,000 after buying an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Natera in the 3rd quarter valued at about $385,000. Everence Capital Management Inc. purchased a new stake in Natera during the fourth quarter valued at about $573,000. Alpha DNA Investment Management LLC bought a new position in Natera during the third quarter worth about $505,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Natera by 50.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock worth $104,000 after purchasing an additional 220 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Canaccord Genuity Group restated a "buy" rating and set a $180.00 price target on shares of Natera in a research note on Wednesday, February 26th. Barclays began coverage on Natera in a report on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 price target for the company. The Goldman Sachs Group boosted their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Guggenheim raised their target price on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Finally, Royal Bank of Canada assumed coverage on Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and a consensus target price of $178.12.

Remove Ads

Insider Buying and Selling

In other news, insider John Fesko sold 663 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the sale, the insider now owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 6,000 shares of Natera stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the transaction, the insider now directly owns 143,768 shares in the company, valued at approximately $20,600,516.72. The trade was a 4.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 306,797 shares of company stock worth $48,940,883 in the last 90 days. 7.60% of the stock is owned by company insiders.

Natera Price Performance

NASDAQ:NTRA traded up $0.75 during midday trading on Tuesday, hitting $154.58. The company had a trading volume of 1,081,574 shares, compared to its average volume of 1,338,057. The company has a market capitalization of $20.90 billion, a PE ratio of -87.83 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00. The stock's fifty day moving average price is $160.92 and its 200-day moving average price is $150.26.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.